Prescription medicine
Methscopolamine First approved as Pamine Forte
Methscopolamine (Pamine Forte) is a prescription medicine with an FDA approval on record since 1953. FDA's NDC Directory lists it from 5 generic labelers, and pharmacies paid $0.608 per methscopolamine brom 2.5 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the methscopolamine FDA label on DailyMed (effective December 10, 2025, Unichem Pharmaceuticals (USA), Inc.); the NDA 8848 record on Drugs@FDA; every methscopolamine label on DailyMed.
Highlights of the record
FDA label of December 10, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageAdjunctive therapy for the treatment of peptic ulcer.
Forms and strengths
- 2.5 mg
- 5 mg
Tablet.
On the market
- Earliest approval on file
- April 9, 1953 Pamine Forte, Fougera; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 5 first October 18, 1976; 3 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 5 of which 5 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.608 per tablet Methscopolamine brom 2.5 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 144 through July 30, 2026
What is methscopolamine used for?
From the label: indications and usageAdjunctive therapy for the treatment of peptic ulcer. METHSCOPOLAMINE BROMIDE HAS NOT BEEN SHOWN TO BE EFFECTIVE IN CONTRIBUTING TO THE HEALING OF PEPTIC ULCER, DECREASING THE RATE OF RECURRENCE OR PREVENTING COMPLICATIONS.
FDA pharmacologic class: Anticholinergic.
Source: FDA drug label (METHSCOPOLAMINE BROMIDE), Unichem Pharmaceuticals (USA), Inc., effective December 10, 2025 (SPL set 5c74bfb0-c80a-4a86-acd1-1e3a1b20255d), via openFDA; the full label on DailyMed
Is there a generic for methscopolamine (Pamine Forte)?
The FDA approved the first generic methscopolamine on October 18, 1976. 5 generic applications are approved; 3 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists methscopolamine from 5 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1953 earliest approval on file
- 1976 first generic approved
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for methscopolamine (Pamine Forte)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.608 per Methscopolamine brom 2.5 mg tablet, down 23% from $0.792 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Methscopolamine brom 2.5 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Methscopolamine brom 2.5 mg tablet | Generic | $0.608 per tablet | $18.23 | -23% |
| Methscopolamine brom 5 mg tablet | Generic | $1.53 per tablet | $45.95 | -2% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for methscopolamine?
The FDA Adverse Event Reporting System holds 144 reports that list methscopolamine among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 5 are coded as a death and 34 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other anticholinergics
- the pharmacologic class, with prices and generics
- Methscopolamine side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other